Tanshinone IIA inhibits angiogenesis in subcutaneous colorectal cancer xenografts in mice

World Chinese Journal of Digestology

Volumn 17, Issue 31, 2009, Pages 3203-3209

  Zhou, Li Hong ^a   Liu, Xuan ^a   Wang, Yan ^a   Fan, Zhong Ze ^a   Sun, Jue ^a   Li, Qi ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Angiogenesis; Colorectal cancer; Mouse; Tanshinone IIA; Vascular endothelial growth factor

Indexed keywords

FLUOROURACIL; TANSHINONE IIA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NONHUMAN; SALVIA MILTIORRHIZA; TUMOR NECROSIS; TUMOR VOLUME; XENOGRAFT;

EID: 75349110250     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v17.i31.3203     Document Type: Article

References (20)

1. Chinese source
2. Chinese source
3. Chinese source
4. Chinese source
5. Chinese source
6. Chinese source
7. Chinese source
8. Iwanuma Y, Chen FA, Egilmez NK, Takita H, Bankert RB. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res 1997; 57: 2937-2942
9. Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Tsukada K, Kuwano H. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 2002; 22: 3977-3984
10. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789-801
11. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974; 19: 331-358
12. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763
13. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23: 576-582
14. Hedley BD, Winquist E, Chambers AF. Therapeutic targets for antimetastatic therapy. Expert Opin Ther Targets 2004; 8: 527-536
15. Chinese source
16. Chinese source
17. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997; 151: 1141-1152
18. Mouta Carreira C, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI, Jain RK. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001; 61: 8079-8084
19. Giatromanolaki A, Koukourakis MI, Stathopoulos GP, Kapsoritakis A, Paspatis G, Kakolyris S, Sivridis E, Georgoulias V, Harris AL, Gatter KC. Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res 2000; 12: 33-41
20. Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Tsukada K, Kuwano H. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 2002; 22: 3977-3984